NSG BioLabs doubles capacity with new site
The expansion aims to facilitate the growth of promising biotech companies.
Singapore's largest biotech incubator, NSG BioLabs, announced a new facility expansion to support more life sciences companies.
The new second level contains a state-of-the-art Bio-Safety Level 2 laboratory that includes millions of dollars of equipment. It increases NSG BioLabs' total built-up area to 22,000 sq ft.
"In light of the current and expected proliferation of biotech startups, we believe our facility expansion comes at the right time. These promising companies need specialised spaces and equipment to innovate, resulting in major demand for high-quality and well-managed laboratory space that must enable both company and sector growth," said CEO and Founder Daphne Teo. "We have been privileged to support our residents in achieving important breakthroughs within our walls, and we are excited to be able to extend the same support to even more biotech innovators."
Established in late 2019, NSG BioLabs aims to provide a conducive environment for biotech companies in Singapore to grow, scale, and commercialise their operations. The facilities currently have over 20 local and foreign biotech residents, specialising in a diverse range of transformative technologies and life-changing applications such as genome editing, tissue engineering, cellular agriculture, cancer immunotherapy, alternative therapies for liver diseases, artificial intelligence, synthetic biology, neurodegeneration drug discovery, and portable testing for COVID-19 and other pathogens.